| Dr Emmett H Broxson Jr, MD | |
|
1 Childrens Plz, Dayton, OH 45404-1898 | |
| (937) 641-3111 | |
| (937) 641-5885 |
| Full Name | Dr Emmett H Broxson Jr |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Pediatric Hematology-oncology |
| Location | 1 Childrens Plz, Dayton, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013023035 | NPI | - | NPPES |
| 0828715 | Medicaid | OH | |
| 0828715 | Other | OH | BCMH |
| 35056878 | Other | ND | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080P0207X | Pediatrics - Pediatric Hematology-oncology | 35056878 (Ohio) | Primary |
| Entity Name | Presbyterian Healthcare Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104802354 PECOS PAC ID: 9234041708 Enrollment ID: O20031103000603 |
News Archive
Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis, today announced that it has signed a non-exclusive agreement with Evrogen (Moscow, Russia) for access to its fluorescent proteins. This license allows Cellectis bioresearch to incorporate these proteins into its own products and will expand the company's offering of genome engineering tools.
S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD).
The Great Recession of 2007-2009 had little direct effect on the health of workers who survived the waves of job cuts that took place during that period, according to a new University of Akron study.
Voters are more willing to pay for a decreased risk of food-related illness than consumers, but female consumers are more willing to pay than male consumers, according to an international team of researchers.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emmett H Broxson Jr, MD 7570 Deep Woods Ct, Springboro, OH 45066-8570 Ph: (937) 748-4534 | Dr Emmett H Broxson Jr, MD 1 Childrens Plz, Dayton, OH 45404-1898 Ph: (937) 641-3111 |
News Archive
Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis, today announced that it has signed a non-exclusive agreement with Evrogen (Moscow, Russia) for access to its fluorescent proteins. This license allows Cellectis bioresearch to incorporate these proteins into its own products and will expand the company's offering of genome engineering tools.
S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD).
The Great Recession of 2007-2009 had little direct effect on the health of workers who survived the waves of job cuts that took place during that period, according to a new University of Akron study.
Voters are more willing to pay for a decreased risk of food-related illness than consumers, but female consumers are more willing to pay than male consumers, according to an international team of researchers.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.
› Verified 1 days ago
Hemanth Shimoga Lingadevaru, MD,MPH,FAAP Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Childrens Plz, Dayton, OH 45404 Phone: 937-641-3000 Fax: 937-641-3107 | |
Tanya Paul, M.D Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Childrens Plz, Dayton, OH 45404 Phone: 937-641-3600 Fax: 937-641-5802 | |
Dr. Sara Frances Guerrero-duby, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1010 Valley St, Dayton, OH 45404 Phone: 937-641-4000 Fax: 937-641-4500 | |
Dr. Rory Jon Peppard, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Wyoming St, Neonatology Office, Dayton, OH 45409 Phone: 937-208-2907 Fax: 937-208-4515 | |
Dr. Ramakrishna Mutyala, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Childrens Plz, Dayton, OH 45404 Phone: 937-641-4000 Fax: 934-641-4500 | |
Bryce Lawrence Willen, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Childrens Plz, Dayton, OH 45404 Phone: 937-641-3600 Fax: 937-641-5802 |